Rejuveron leads €15.7m series B in Rejuvenate Biomed

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Investment in Rejuvenate Biomed set to accelerate clinical development of its sarcopenia treatment for healthy aging.

Rejuveron Life Sciences, a Zürich-based biotechnology company developing therapies to promote healthy aging, has announced that it will ultimately acquire a majority shareholding in Rejuvenate Biomed, a Belgium-based biomedical company developing novel combination drugs for age-related diseases.

Longevity.Technology: Addressing the challenges of aging is top of Rejuvenate Biomed’s agenda and this investment is added firepower that will propel its research. Sarcopenia may not generate the same number of headlines as Alzheimer’s or cardiovascular disease, but it has enormous unmet medical need and places a significant burden on individuals, as well as support systems and healthcare – and the key risk factor is age.

Sarcopenia is devastating and progressive loss of skeletal muscle mass and strength that strictly correlates with physical disability, poor quality of life and death, and Rejuvenate Biomed is moving towards tackling it by creating synergistic combination products that repurpose existing compounds but improve them with its own proprietary research. 

The €15.7 million Series B funding, led by Rejuveron and Luxembourg-based Vesalius Biocapital, is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).

Rejuvenate aims to increase people’s healthy years of life by translating the science behind what keeps cells vital and resilient into human therapeutics. The company has developed a proprietary in silico screening platform that uses an approach based on AI and network biology to investigate dysregulated pathways in aging. With this platform, Rejuvenate is able to evaluate if safe, marketed treatments can be used as synergistic drug combinations to impact upon these pathways, maintaining our natural cellular resilience and postponing the onset of certain age-related diseases.

Rejuvenate’s lead drug candidate RJx-01 is a novel, small molecule, combination product identified using the company’s in silico platform. RJx-01 is being developed for the treatment of acute and chronic sarcopenia, a muscle disease defined by the loss of muscle strength, quality, and mass. There is a huge unmet medical need in sarcopenia: the disease affects 50% of elderly and rehabilitation patients, and there is no approved therapy on the market.

In vivo studies with RJx-01 have demonstrated the treatment’s ability to improve muscle mass and strength, as well as beneficial effects in the prevention and treatment of other age-related diseases. Rejuvenate’s Series B will now be used to advance RJx-01 through a Belgian Phase Ib clinical trial and an international multicentre Phase IIb trial. The funds will also go towards exploring the treatment’s potential in other diseases, as well as further developing the company’s in silico screening platform and pipeline of other drug candidates.

Dr Matthias Steger, PhD, MBA, CEO of Rejuveron said: “Over the past four years, the Rejuvenate team has demonstrated that its approach can be used to develop new patent-protected combination drugs based on known prescription medicines. This platform has resulted in a promising first drug candidate, with the wider application being to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. This strikes right at the heart of Rejuveron’s purpose: making therapies happen for people to stay healthier for longer.”

Dr Ann Beliën, PhD, Founder and CEO of Rejuvenate said: “This investment is more to us than a financial deal; it is the result of Vesalius Biocapital’s unrelenting belief in what we do, and the backing of Rejuveron, a company with which we share a fully aligned vision and complementary expertise. This investment will result in an intense collaboration between the Rejuveron and Rejuvenate teams, lifting us all to the next level. Becoming a clinical-stage company is a key milestone for us, and we could not have reached this point without the dedication of our excellent team and the continued support of our investors. We look forward to a future where products from our platform help people live healthier lives.”

Mr Stéphane Verdood, MBA, MSc, Managing Partner at Vesalius Biocapital III said: “Vesalius Biocapital III has supported Rejuvenate since the company’s inception. Its excellent scientific basis, sound clinical approach and strong management team convinced us to invest at an early stage of development. The current round will allow Rejuvenate to reach proof of concept in an underserved medical area, and we are pleased that Rejuveron shares this drive.”

Combining existing medicines to target aging – our interview with Dr Ann Beliën

Image courtesy of Dr Ann Beliën
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Michael Antonov: longevity is all about tackling true unknowns

The Co-founder of Formic Ventures is using logic and innovation to drive the longevity sector forward. Michael Antonov is a serial entrepreneur and philanthropist who...

Shooting for the moon means going down the rabbit hole

Scientific co-operation, research collaboration and alternative financial incentives – Moon Rabbit is a crypto-conglomerate on a longevity mission. Moon Rabbit is on a mission to...